[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201408500RA - Antibody producing non-human mammals - Google Patents

Antibody producing non-human mammals

Info

Publication number
SG10201408500RA
SG10201408500RA SG10201408500RA SG10201408500RA SG10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA
Authority
SG
Singapore
Prior art keywords
human
nucleic acid
antibody producing
cells
producing non
Prior art date
Application number
SG10201408500RA
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Robert Arjen Kramer
Kruif Cornelis Adriaan De
Original Assignee
Merus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201408500R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus B V filed Critical Merus B V
Publication of SG10201408500RA publication Critical patent/SG10201408500RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201408500RA 2008-06-27 2009-06-29 Antibody producing non-human mammals SG10201408500RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27

Publications (1)

Publication Number Publication Date
SG10201408500RA true SG10201408500RA (en) 2015-01-29

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Country Status (23)

Country Link
EP (6) EP2147594B1 (fr)
JP (6) JP5749161B2 (fr)
KR (5) KR102306491B1 (fr)
CN (3) CN102123582B (fr)
AU (1) AU2009263082C1 (fr)
CA (1) CA2729095C (fr)
CY (2) CY1114830T1 (fr)
DK (3) DK2556747T3 (fr)
ES (3) ES2906344T3 (fr)
HK (1) HK1154463A1 (fr)
HR (2) HRP20220205T1 (fr)
HU (1) HUE057994T2 (fr)
LT (1) LT3456190T (fr)
MX (1) MX2010014542A (fr)
NZ (1) NZ590118A (fr)
PL (2) PL2147594T3 (fr)
PT (3) PT3456190T (fr)
RS (2) RS62925B1 (fr)
RU (2) RU2731084C2 (fr)
SG (3) SG10201408500RA (fr)
SI (2) SI2147594T1 (fr)
WO (1) WO2009157771A2 (fr)
ZA (1) ZA201009312B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
ES2906344T3 (es) * 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
CA3038954A1 (fr) 2008-09-30 2010-04-08 Ablexis, Llc Mammiferes non humains destines a la production d'anticorps chimeriques
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN105340834B (zh) 2009-07-08 2018-11-06 科马布有限公司 动物模型及治疗分子
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9580491B2 (en) 2010-03-31 2017-02-28 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
AU2011285919C1 (en) * 2010-08-02 2015-09-17 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising VL domains
DK3572517T3 (da) * 2011-08-05 2021-06-14 Regeneron Pharma Humaniserede, universelle letkæde-mus
JP5813880B2 (ja) * 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
WO2013045916A1 (fr) 2011-09-26 2013-04-04 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
CA2791109C (fr) * 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2794878T1 (sl) 2011-12-22 2020-07-31 F. Hoffmann-La Roche Ag Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov
DK2809150T3 (da) * 2012-02-01 2019-12-09 Regeneron Pharma Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
CN104244709B (zh) * 2012-03-06 2017-03-08 瑞泽恩制药公司 共同轻链小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2013204579B2 (en) 2012-03-16 2016-01-14 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
CN106318951A (zh) 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CA2871068C (fr) 2012-04-20 2022-06-14 Merus B.V. Procedes et moyens de production de molecules de type ig
JP2015525071A (ja) * 2012-06-05 2015-09-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法
EP2869845B1 (fr) 2012-07-06 2019-08-28 Genmab B.V. Protéine dimérique ayant des mutations triples
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
KR102295842B1 (ko) * 2013-03-13 2021-08-31 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 경쇄 레퍼토리를 발현하는 마우스
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
ES2715949T3 (es) * 2013-10-15 2019-06-07 Regeneron Pharma Animales con IL-15 humanizada
CA2935077C (fr) 2013-12-27 2022-03-15 Geoffrey C. Winters Systemes de liaison contenant un sulfonamide pour conjugues de medicaments
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
LT3805268T (lt) 2014-02-28 2025-01-27 Merus N.V. Antikūnas, surišantis erbb-2 ir erbb-3
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
CA2960899C (fr) 2014-09-17 2021-08-17 Zymeworks Inc. Composes cytotoxiques et antimitotiques et leurs procedes d'utilisation
EP3271403A1 (fr) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus N.V. Human CD3 binding antibody
WO2017035241A1 (fr) 2015-08-24 2017-03-02 Trianni, Inc. Production améliorée d'immunoglobulines
US11939394B2 (en) 2015-10-23 2024-03-26 Merus N.V. Binding molecules that inhibit cancer growth
WO2017095939A1 (fr) 2015-12-03 2017-06-08 Trianni, Inc. Diversité améliorée d'immunoglobulines
CA3012833A1 (fr) 2016-02-04 2017-08-10 Trianni, Inc. Production amelioree d'immunoglobulines
AU2017272337C1 (en) * 2016-06-03 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2018029534A1 (fr) 2016-08-12 2018-02-15 Oxitec Ltd. Gène spécifique du sexe à auto-limitation et procédés d'utilisation
IL265541B2 (en) 2016-09-23 2024-08-01 Merus Nv Bispecific antibodies and compositions comprising thereof for treating cancer
JP2020509780A (ja) * 2017-03-20 2020-04-02 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細胞並びにその使用方法及び製造方法
AU2018246872C1 (en) 2017-03-31 2023-05-18 Merus N.V. ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
AU2018271157C1 (en) 2017-05-17 2021-11-18 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
KR20200037250A (ko) 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
KR102715567B1 (ko) 2017-07-06 2024-10-14 메뤼스 엔.페. 세포에 의해 발현된 생물학적 활성을 조정하는 결합 분자
TW201920657A (zh) 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
WO2019031965A1 (fr) 2017-08-09 2019-02-14 Merus N.V. Anticorps qui se lient à l'egfr et à cmet
WO2019108065A1 (fr) 2017-12-01 2019-06-06 Merus N.V. Utilisation d'un anticorps bispécifique et d'il-15 en polythérapie
WO2019113065A1 (fr) * 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Animaux non humains présentant une chaîne légère d'immunoglobuline lambda modifiée et leurs utilisations
TW202438530A (zh) 2018-02-09 2024-10-01 日商小野藥品工業股份有限公司 雙特異性抗體
PT3772927T (pt) 2018-03-24 2025-01-24 Regeneron Pharma Animais não humanos geneticamente modificados para gerar anticorpos terapêuticos contra complexos péptido-mhc, métodos de produção e usos dos mesmos
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
WO2019236671A1 (fr) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Animal transgénique pour produire des anticorps diversifiés ayant la même chaîne légère ii
LT3629720T (lt) 2018-06-14 2022-03-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą
US11873338B2 (en) 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
US20220090125A1 (en) 2018-12-21 2022-03-24 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN113227132A (zh) * 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
SG11202105926QA (en) 2018-12-31 2021-07-29 Merus Nv Truncated multivalent multimers
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
AU2020222749A1 (en) 2019-02-14 2021-09-02 Merus N.V. Combinations of binding moieties that bind EGFR, HER2 and HER3.
JP7375027B2 (ja) 2019-02-14 2023-11-07 メルス ナムローゼ フェンノートシャップ ２つ以上の抗体を含む組成物の製造
JP2022521358A (ja) 2019-02-18 2022-04-06 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP2022534674A (ja) 2019-05-09 2022-08-03 メルス ナムローゼ フェンノートシャップ タンパク質を多量体化する変異体ドメイン及びその分離
WO2021003149A1 (fr) * 2019-07-01 2021-01-07 Trianni, Inc. Animaux transgéniques et leurs procédés d'utilisation
WO2021006199A1 (fr) * 2019-07-05 2021-01-14 小野薬品工業株式会社 Traitement du cancer hématologique avec une protéine à double spécificité pd-1/cd3
PH12022550190A1 (en) 2019-07-30 2022-11-21 Ono Pharmaceutical Co Bispecific antibody
EP3772518A1 (fr) 2019-08-07 2021-02-10 Merus N.V. Domaines variables humains modifiés
KR20220048015A (ko) 2019-08-19 2022-04-19 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체와 토포아이소머라제 i 억제제의 병용을 이용한 암의 치료
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
KR20230145542A (ko) 2019-12-24 2023-10-17 메뤼스 엔.페. Tgf-베타-rii 결합 단백질
CA3166407A1 (fr) 2020-01-29 2021-08-05 Merus N.V. Moyens et procede permettant de moduler les effets d'engagement de cellules immunitaires
CN115698067A (zh) 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
EP4158034A4 (fr) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Animaux non humains génétiquement modifiés ayant un locus d'immunoglobuline à chaine légère
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
MX2023006983A (es) 2020-12-15 2023-06-26 Merus Nv Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CN116710486A (zh) 2020-12-16 2023-09-05 美勒斯公司 用于治疗癌症的多特异性抗体
KR20230132465A (ko) 2020-12-18 2023-09-15 메뤼스 엔.페. 항체 조성물
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
CA3237654A1 (fr) 2021-10-06 2023-04-13 Merus N.V. Traitement de cancers traites par un inhibiteur de point de controle immunitaire ayant une expression d'egfr elevee a l'aide d'un anticorps se liant au moins a l'egfr
EP4469476A1 (fr) 2022-01-25 2024-12-04 Merus N.V. Polythérapie pour le traitement du cancer
TW202337909A (zh) 2022-03-07 2023-10-01 荷蘭商美勒斯公司 包括結合EGFR及cMET之抗體的組合療法
EP4490190A1 (fr) 2022-03-07 2025-01-15 Merus N.V. Traitement avec un anticorps qui se lie à egfr et à cmet
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
TW202432605A (zh) 2022-12-23 2024-08-16 荷蘭商美勒斯公司 使用至少結合ｅｇｆｒ的抗體和免疫檢查點抑制劑組合治療癌症
WO2024144401A1 (fr) 2022-12-28 2024-07-04 Merus N.V. Traitement du cancer avec une combinaison d'un anticorps qui se lie à l'egfr et de médicaments cytotoxiques

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (fr) * 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
JPH07503132A (ja) * 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
CA2288600C (fr) 1997-05-02 2010-06-01 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
CN1161614C (zh) * 1998-03-30 2004-08-11 研究发展基金会 用促肾上腺皮质素释放因子受体-1缺陷型小鼠鉴定促效剂和拮抗剂的方法
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
EP1439234A1 (fr) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Transgénèse ciblée utilisant le locus 26
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
EP1737971B1 (fr) 2004-01-20 2017-08-16 Merus N.V. Mélanges de proteines de liason
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
CA2604440A1 (fr) * 2005-04-29 2006-11-09 Inserm (Institut De La Sante Et De La Recherche Medicale) Animaux transgeniques et procedes de fabrication d'anticorps recombines
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
MEP11109A (en) 2006-10-02 2011-12-20 High affinity human antibodies to human il-4 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
ES2547142T5 (es) * 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón

Also Published As

Publication number Publication date
CN102123582B (zh) 2015-09-30
RU2559524C2 (ru) 2015-08-10
SI3456190T1 (sl) 2022-06-30
JP7439201B2 (ja) 2024-02-27
EP3456191A1 (fr) 2019-03-20
CA2729095C (fr) 2018-12-04
SG10201914027VA (en) 2020-03-30
KR102306491B1 (ko) 2021-09-29
EP2147594A1 (fr) 2010-01-27
WO2009157771A3 (fr) 2010-02-18
AU2009263082B2 (en) 2014-03-20
JP5749161B2 (ja) 2015-07-15
CY1125119T1 (el) 2023-06-09
AU2009263082A1 (en) 2009-12-30
RU2015119670A (ru) 2015-12-10
LT3456190T (lt) 2022-03-10
KR101990228B1 (ko) 2019-06-17
PT3456190T (pt) 2022-02-15
KR20110029156A (ko) 2011-03-22
JP2017121256A (ja) 2017-07-13
RU2011102962A (ru) 2012-08-10
ES2853226T3 (es) 2021-09-15
MX2010014542A (es) 2011-04-05
KR102261586B1 (ko) 2021-06-08
KR20200057093A (ko) 2020-05-25
DK3456190T3 (da) 2022-02-14
JP7242611B2 (ja) 2023-03-20
EP3456192A1 (fr) 2019-03-20
HRP20220205T1 (hr) 2022-05-27
EP2147594B1 (fr) 2013-11-13
PT2147594E (pt) 2014-02-17
HUE057994T2 (hu) 2022-06-28
HK1154463A1 (zh) 2012-04-27
ES2906344T3 (es) 2022-04-18
DK2556747T3 (da) 2021-02-15
EP2556747A2 (fr) 2013-02-13
EP3456190B1 (fr) 2021-11-24
EP2556747B1 (fr) 2020-12-02
RU2731084C2 (ru) 2020-08-28
SI2147594T1 (sl) 2014-02-28
RU2015119670A3 (fr) 2019-01-22
PL2147594T3 (pl) 2014-04-30
JP2020191882A (ja) 2020-12-03
KR102112655B1 (ko) 2020-05-19
CY1114830T1 (el) 2016-12-14
AU2009263082B9 (en) 2014-07-17
PL3456190T3 (pl) 2022-06-06
JP2024063038A (ja) 2024-05-10
AU2009263082C1 (en) 2018-11-01
HRP20140139T1 (hr) 2014-03-14
SG10201914019YA (en) 2020-03-30
KR20140127914A (ko) 2014-11-04
NZ590118A (en) 2012-10-26
CN105191863B (zh) 2020-12-22
JP6824807B2 (ja) 2021-02-03
JP2022188085A (ja) 2022-12-20
JP2015156871A (ja) 2015-09-03
EP2556747A3 (fr) 2016-08-03
JP2011525808A (ja) 2011-09-29
RS62925B1 (sr) 2022-03-31
WO2009157771A2 (fr) 2009-12-30
ES2445193T3 (es) 2014-02-28
CA2729095A1 (fr) 2009-12-30
KR20170066688A (ko) 2017-06-14
KR20190025068A (ko) 2019-03-08
RS53146B (en) 2014-06-30
ZA201009312B (en) 2011-08-31
DK2147594T3 (da) 2014-02-10
PT2556747T (pt) 2021-02-15
EP3456193A1 (fr) 2019-03-20
CN112481300A (zh) 2021-03-12
CN102123582A (zh) 2011-07-13
RU2020127564A3 (fr) 2022-02-21
RU2020127564A (ru) 2022-02-21
EP3456190A1 (fr) 2019-03-20
CN105191863A (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
SG10201408500RA (en) Antibody producing non-human mammals
DK1391511T3 (da) Humant kunstigt kromosom indeholdende human antistof lambda-let-kæde-gen
JP2020191882A5 (fr)
Jonas et al. Genomic selection needs to be carefully assessed to meet specific requirements in livestock breeding programs
RU2008134517A (ru) Получение антител из одних тяжелых цепей в трансгенных животных
MXPA06000562A (es) Loci de inmunoglobulina humanizada.
NZ597481A (en) Animal models and therapeutic molecules
IL202302A (en) Methods for producing non-human germ cells having an inactivated ig locus, transgenic animals comprising same and monoclonal antibodies produced therein
MX2011007660A (es) Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
JP2012532598A5 (fr)
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
WO2004024871A3 (fr) Anticorps et methodes de creation d'anticorps genetiquement modifies a forte affinite
GB0110029D0 (en) Transgenic animal
ATE363068T1 (de) Produktion eines monoklonaken antikörpers durch eine transgene vogelspezies
GB2272440A (en) Transgenic non-human animals capable of producing heterologous antibodies
RU2012128856A (ru) Мыши, которые производят антитела, имеющие только тяжелую цепь
NO20090424L (no) Humane antistoffer mot ErbB2
WO2008027986A3 (fr) Expression renforcée d'immunoglobuline humaine ou humanisée chez des animaux transgéniques non humains
BR112013027420A2 (pt) "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos".
HN2004000285A (es) ANTICUERPOS DIRIGIDOS A c-MET
TR201909967T4 (tr) Histidin ile işlenmiş hafif zincirli antikorlar ve bunu üretmeye yönelik genetik olarak modifiye edilmiş insan olmayan hayvanlar.
JP2009502203A5 (fr)
MX2021014893A (es) Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
ATE513852T1 (de) Verfahren, das ein transgenes tier mit erhöhter immunreaktion benutzt
ATE464389T1 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind